Skip to content
Screener

Xeris Biopharma Holdings, Inc. XERS EV / EBITDA

EV / EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
31.3×-7.9×
Corcept Therapeutics logo
Corcept TherapeuticsCORT
1,093.2×+1,015×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
525.2×—
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
7.9×—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
7.7×-10.6×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
4.3×-1.7×

Other financials

Income statement

See full
Revenue$92.1M+28.7%
Gross profit$79.6M+33.4%
Operating income$5.2M+15.4%
Net income-$31.1M-1,513%
EPS (diluted)-$0.18-1,700%

Balance sheet

See full
Cash & equivalents$121.7M+105%
Total debt$289.4M+12.5%
Total equity-$9.7M+49.6%
Total assets$411.9M+23.1%

Cash flow

See full
Operating cash flow$8.3M+4,440%
CapEx$131.0K—
Free cash flow-$29.1M—

Valuation

See full
Market cap$1.27B+24.4%
Enterprise value$1.44B+18.6%
P/S3.8×-0.4×

Profitability

See full
Gross margin86.6%+4.3pp
Operating margin10.9%+8.4pp
Net margin-5.1%-1.9pp

Returns & leverage

See full
Return on equity-209.8%—
Debt / equity19.9×—
Current ratio1.4×-0.5×

Where this comes from

Calculated from Xeris Biopharma Holdings, Inc.’s reported figures.

enterprise value/ebitda=40.5×

Based on the most recent quarter.

The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001867096-26-000065

FAQ

What is Xeris Biopharma Holdings, Inc.'s EV / EBITDA?
Xeris Biopharma Holdings, Inc. (XERS) reported EV / EBITDA of 40.5× in Q2 2026.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Xeris Biopharma Holdings, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude